Why can t 1.2 million anti cancer drugs be covered by medical insurance?

In 2021, 74 new drugs were added to the list of medical insurance drugs, and one of the drugs required for rare diseases of newborns was also included in the medical insurance list. This news is very good news for many parents of children, which makes them less financially burdened and can afford to see a doctor. So why can't 1.2 million anti-cancer drugs be covered by medical insurance?

Introduction to the list of medical insurance drugs.

I believe that many people know the list of medical insurance drugs, if this drug enters the list of medical insurance drugs, then this drug can be reimbursed by medical insurance, which will reduce the burden of many families to see a doctor, so that they can see the disease, and more people will not worry about their own diseases. Therefore, if the new drugs added to the medical insurance drug list are a great blessing for many patients, it can only reduce their burden of seeing a doctor and make their family financial burden no longer so heavy. Therefore, I think that the list of medical insurance drugs is indeed very good, which can make more poor people afford to see a doctor.

Why can't 1.2 million injections of anti-cancer drugs be covered by medical insurance?

I also made some inquiries on the Internet and found that the ** of anti-cancer drugs is very expensive, reaching 1.2 million injections, which is a sky-high price for many cancer patients, and they can't afford it. However, I also checked a lot of news and found that this anticancer drug is indeed not included in the medical insurance list, because the ** of anticancer drugs is very expensive, and this anticancer drug is not within the scope of the state's responsibility. But it is also believed that with the development of medical insurance, this anti-cancer drug may also enter the medical insurance list, which will benefit more cancer patients and make them able to afford to see the disease.

Summary. Therefore, when we see the medical insurance list, we should not blame the country, but should thank the country for its contribution. It is also believed that with the development of medical insurance, 1.2 million injections of anti-cancer drugs may enter the list of medical insurance drugs.

Because the efficacy of such a drug is relatively good, the cost is relatively high, and the number of developed drugs is particularly small, and it is also relatively expensive.

Because this thing is very expensive, and the raw materials are also very expensive, if it is included in the medical insurance, it may cause the country to lose a lot.

Because this anti-cancer drug is very expensive, and the cost of development is also very high, so such a drug cannot be included in the medical insurance, otherwise it will bring great economic pressure and burden to the country.

1.2 million injections of anti-cancer drugs are not reimbursed by medical insurance. 1.2 million injections of anti-cancer drugs have not been included in medical insurance, but many places across the country have been included in Huimin Insurance. Medical insurance generally refers to basic medical insurance, which is a social insurance system established to compensate workers for economic losses caused by the risk of disease.

Through the employer and individual payment, the establishment of medical insurance**, after the insured person is sick and incurs medical expenses, the medical insurance institution will give him a certain amount of economic compensation.

Legal basisArticle 28 of the Social Insurance Law of the People's Republic of China.

Medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facility standards, and emergency and rescue medical expenses shall be paid from the basic medical insurance in accordance with national regulations.

What is the process of medical insurance payment?

1. Application acceptance. The collection department of the medical insurance institution accepts the "Declaration Form for Change of Medical Insurance Payment Base" filled in by the insured unit, and requires the corresponding information;

2. Payment verification.

1) The collection department of the medical insurance institution shall review the payment declaration and verification ** and relevant information filled in by the insured unit. After the examination is passed, the procedures for the verification or increase or decrease of the insured personnel shall be handled;

2) According to the payment declaration and verification situation, the collection department of the medical insurance institution shall record the insurance time, current payment salary and other information for the newly insured persons in a timely manner. The collection department of the medical insurance institution shall verify the current payment base according to the declaration of the insured unit;

3. Fee collection. Medical insurance institutions can charge fees through the opening bank of "income account deposit", or they can collect fees by check, cash, wire transfer, cashier's check, etc., and issue special collection vouchers;

4. Pay the arrears. According to the arrears of medical insurance, the collection department of the medical insurance institution shall establish the arrears data and information, fill in the "Notice of Supplementary Payment of Social Insurance Premiums", and notify the insured units to make up the arrears.

It's the annual medical insurance negotiation again, although the negotiators are as good as ever, but the 1.2 million anti-cancer drugs that everyone is thinking about still fail to negotiate and are not included in the medical insurance. <>

In fact, the failure of the negotiation of 1.2 million anti-cancer drugs is inevitable, in the medical insurance negotiations, the biggest advantage of negotiators is that the demand is relatively large, but the 1.2 million anti-cancer drugs are relatively targeted, and can only target specific ** or metastatic diffuse large B-cell lymphoma, and it needs to be customized, although the effect is very good, many people want to use it, but not everyone can use it. It can be seen from the bills circulating on the Internet that the sale of this anticancer drug is a certain biotechnology ****, not the designated hospital of the second level and above agreed in the insurance terms, so the 1.2 million anticancer drugs are purchased drugs in the medical insurance, and the insurance company's million medical insurance cannot be reimbursed, in this way, only by buying enough critical illness insurance can the anxiety caused by the 1.2 million anticancer drugs be resolved, after all, it is easier to buy 1.2 million insurance than to earn 1.2 million. <>

Although the insurance premium of 1.2 million critical illness is much less, if all the people in the family are equipped with 1.2 million critical illness protection, it is also a large expense, whether you suffer from diffuse large B-cell lymphoma is not necessarily, but the annual insurance premium must be paid, buy insurance to make life better, if you are poor because of buying insurance, it is not good, especially once one day the family is in a financial situation, and you can't pay the insurance premium to surrender the insurance, then the loss will be greater. <>

Not long ago, the China Banking and Insurance Regulatory Commission issued the "Notice on Further Regulating the Internet Life Insurance Business of Insurance Institutions", and it will be a good start to 2022 in more than a month, so some people want to take advantage of the supervision to hype a wave of sales stoppage. In fact, the purpose of the notice is mainly to standardize the sales process, forcing insurance companies to improve after-sales service, some insurance companies often engage in some "first month" 0 "yuan, long insurance short do" products to mislead consumers, insurance companies think they write very clearly, but in fact, ordinary people look like a book from heaven.

Because these anti-cancer drugs** are more expensive, and the production cost is also high, many drugs need to be imported, so they will not be covered by medical insurance.

Because the cost of this drug is so expensive, I can't get medical insurance, which I think is a normal thing, but I believe that it will improve in the future.

Because this is not in line with the relevant national regulations. **The high cost of anti-cancer drugs on medical insurance will increase the pressure on medical insurance in some aspects to a certain extent, and at the same time, it will make the country bear higher medical costs.

After testing, this anti-cancer drug is indeed very effective, but it cannot be ignored that it is also very expensive. The average price of this anti-cancer drug on the market has reached 1.2 million yuan per injection, no matter what kind of family, 1.2 million is not a small number, not to mention that for families with poor economic ability, 1.2 million is an absolute sky-high price. Therefore, if this drug can be included in medical insurance, then it will bring good news to many families of cancer patients.

Even if it can only be used for lymphoma, it can save a lot of lives.

This anti-cancer drug is mainly used for lymphoma, and it is not possible to do any cancer for the time being. Therefore, citizens should still keep a normal mind and not be misjudged by the deliberate propaganda of some ** and misjudge the miracle of this anti-cancer drug.

Diffuse large B-cell lymphoma that can hide in the body's immune cells.

First, I think a needle of ** can be cut to less than 1 million yuan.

Second, what is the function of this medicine?

Third, after being included in medical insurance, it can help others pay a little less.

The ** of this drug can probably only be cut to about 1 million yuan, because the cost of the drug is there, and I don't think I can cut a lot of money no matter how much I cut it.

I think that if you enter the medical insurance, you will have to cut at least two-thirds of the ** of this drug. 1.2 million yuan, it should be 400,000 yuan. This is really a particularly good news, kudos to the country.

I think this drug should be able to cut a relatively low **, it will be less than a million, because this ** is really high, and you need to cut more.

Summary. CAR-T is indeed a very good way, and the two CAR-T models that have been marketed in China are written for diffuse large B lymphoma (the most common one in lymphoma). Director Wu Huijing said that taking diffuse large B lymphoma after the failure of the second line ** as an example, the remission rate of CAR-T is 70%-90%, which is almost higher than that of all drugs, and the complete remission rate is 50%-60%.

However, about half of patients within 1 year**, even if a complete remission is achieved, there is still a chance of **.

1.2 million anti-imitation Tongfu cancer injection is not a scam to carry the bureau, 1.2 million yuan of anti-cancer drugs for a shot or let the cancer cells be cleared" Lunbi's report, this drug is called CAR-T drug, and the drug name is axileucel injection, which has been approved for marketing in China.

CAR-T is indeed a very good way, and the two CAR-T models that have been listed in China are both diffuse large B lymphoma (the most common one in lymphoma). Director Wu Huijing said that in the case of diffuse large B lymphoma after the failure of the second line, the remission rate of CAR-T is 70%-90%, which is almost higher than that of all drugs, and the complete remission rate is 50%-60%. However, about half of patients within 1 year**, even if a complete remission is achieved, there is still a chance of **.

1.2 million injections of "anti-cancer miracle drug" for medical insurance negotiations, to be honest, no one can say how much can be cut, but I think that it is basically impossible to "within 100,000 yuan" and "within 10,000 yuan" expected by netizens, after all, the cost is there. We still have to wait for the official announcement of how much it will cost at our own expense in the future, and how much this anti-cancer miracle drug will sell depends on the negotiation results of the Health Insurance Bureau.

At present, the price of the drug is too high to exceed the affordability of ordinary families, and the Health Insurance Bureau is actively negotiating with pharmaceutical companies this time, hoping that the drug can be reduced and widely sold in the Chinese market to save more and more cancer patients. It is believed that through the unremitting efforts of the Medical Insurance Bureau, the ** of this drug can be lowered.

Among the drugs participating in the negotiation this time, the most concerned is the popular "anti-cancer miracle drug", which is rumored on the Internet that cancer cells can be cleared with one injection. However, only 1 injection costs 1.2 million yuan, which is really sky-high, and many families cannot afford it, but medical insurance negotiations may be able to reduce some of the burden.

Medical insurance negotiation refers to the negotiation between experts from the National Health Insurance Administration and pharmaceutical companies to negotiate drugs, so as to reduce drugs, reduce the economic pressure of patients, and solve the problems of difficult and expensive drugs for countless families. You can find that expensive drugs such as the new anti-tumor drug PD-1 and sintilimab have become "people-friendly" because of medical insurance.

At present, two CAR-T products have been approved in China, including: Fosun Kite's Axileucel Injection (trade name: Yikaida) and JW Therapeutics' Relma-Orencel Injection (trade name:

However, due to the medical insurance negotiation rules, the participating products need to be approved for marketing before June 30, and the latter is a product approved in September, so it will not participate in this negotiation. So this CAR-T is the "standout" in this negotiation arena.

However, I have to say one thing about the "anti-cancer miracle drug", which actually needs to be "privately customized". Patients need a doctor's professional evaluation to determine whether the ** is suitable for use. Because CAR-T needs to extract T cells from the patient's body, it only has a specific effect on the currently fixed patients, and cannot be mass-produced and then applied to others; Among them, it is also necessary to take into account the cumbersome formulation process such as the experimentation and training of professionals, so there is a reason why it is more expensive.

However, with the emergence of domestic innovative drugs, homogeneous competition is also more serious, many companies will choose to significantly reduce prices in order to gain a larger market share in order to obtain the qualification to enter the medical insurance and the huge advantage compared with competing products, so there will be a wonderful battle on the negotiation field, hoping that with time, more good drugs will be included in the medical insurance, reduce the burden of patients, and benefit the people!

In the future, it is estimated that it will cost about 300,000 yuan at out-of-pocket expense, and if it is included in the medical insurance, the medical insurance will bear most of the cost, and the individual will only bear about 30%.

In the future, it may cost tens of thousands of yuan or hundreds of thousands of yuan at its own expense, and now this ** is indeed very high, and it should be reduced a lot after the negotiation, and it will not continue to be so high**.